Extensive Multiple Sclerosis Reactivation After Switching From Fingolimod to Rituximab

Case Reports in Neurological Medicine
doi 10.1155/2018/5190794
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

Predictors for Multiple Sclerosis Relapses After Switching From Natalizumab to Fingolimod

Multiple Sclerosis
Neurology
2014English

Long-Term Evaluation of NEDA-3 Status in Relapsing-Remitting Multiple Sclerosis Patients After Switching From Natalizumab to Fingolimod

Therapeutic Advances in Neurological Disorders
NeurologyPharmacology
2018English

Correction To: Switching From Natalizumab to Fingolimod Treatment in Multiple Sclerosis: Real Life Data From the Austrian MS Treatment Registry

Journal of Neurology
Neurology
2019English

Debate on the Treatment of Multiple Sclerosis: Experience From an Intractable Multiple Sclerosis Case With Rebound Syndrome After Fingolimod Cessation

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2019English

Tumefactive Multiple Sclerosis Lesions Under Fingolimod Treatment

Neurology
Neurology
2012English

Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis

Case Reports in Medicine
Medicine
2012English

Natalizumab Versus Fingolimod and Dimethyl Fumarate in Multiple Sclerosis Treatment

Annals of Clinical and Translational Neurology
NeuroscienceNeurology
2018English

Myeloid Cells as Target of Fingolimod Action in Multiple Sclerosis

Neurology: Neuroimmunology and NeuroInflammation
Neurology
2015English

Fingolimod (FTY720) as an Anti-Multiple Sclerosis Oral Ultimate Therapy

Biosciences Biotechnology Research Asia
BiotechnologyAgronomyCrop ScienceDrug Discovery
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy